

**Disclosure Purpose:** 21-19912.R1

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



# Lindsey Baden

Disclosure Purpose: 21-19912.R1

## Summary of Interests

### Company or Organization

| Entity  | Type             | Interest Held By  |
|---|------------------|---|
| <a href="#">Bill and Melinda Gates Foundation</a>   | Grant / Contract | Self  |
| <i>Recipient Name:</i> Lindsey Baden<br><i>Grant / Contract Description:</i> Vaccine and mAb development for Infectious Diseases<br><i>Additional Information:</i>                  |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Harvard Medical School</a>  | Grant / Contract | Self  |
| <i>Recipient Name:</i> Lindsey Baden<br><i>Grant / Contract Description:</i> Support clinical research, Covid response<br><i>Additional Information:</i>                            |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Massachusetts Medical Society</a>   | Other            | Self  |
| <i>Category:</i> Other<br><i>Additional Information:</i>  |                  | <i>Description:</i> Deputy Editor, New England Journal of Medicine              |
| <a href="#">National Institutes of Health</a>   | Grant / Contract | Self  |
| <i>Recipient Name:</i> Lindsey Baden<br><i>Grant / Contract Description:</i> NIAID, NCATS. Support multiple activities: vaccine development, CTSA<br><i>Additional Information:</i> |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Wellcome Trust</a>  | Grant / Contract | Self  |
| <i>Recipient Name:</i> Lindsey Baden<br><i>Grant / Contract Description:</i> Develop Cholera Vaccine<br><i>Additional Information:</i>  |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

a. **Please describe those relationships.**

Dr. Baden reports grants from NIH/NIAID for the conduct of this study; in addition grants from NIH/ NIAID, Gates Foundation, and Wellcome Trust, outside the submitted work; and Dr. Baden is a Deputy Editor at the New England Journal of Medicine. Dr. Baden is involved in HIV, other pathogens, and COVID vaccine clinical trials conducted in collaboration with the NIH, HIV Vaccine Trials Network (HVTN), COVID Vaccine Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI), Crucell/Janssen, Moderna, Military HIV Research Program (MHRP), Gates Foundation, and the Ragon Institute.

2. **What is the manuscript title?**

SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19912.R1

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By             |
|--|------------|------------------------------|
| Moderna  | Employment | Self                         |
| <i>Title:</i><br>Additional Information: Full-time employee, own stock |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19912.R1

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By             |
|--|------------|------------------------------|
| Moderna Therapeutics   | Employment | Self                         |
| <i>Title:</i> VP of Clinical Development<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19912.R1

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By                                      |
|--|------------|---|
| Center for AIDS Research, Duke University                          | Employment | Self  |
| <i>Title:</i> Project Planner II<br><i>Additional Information:</i> |            | <i>Position Description:</i> Research Project Manager |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization  |            |   |
|--|------------|---|
| Entity   | Type       | Interest Held By                                      |
| Moderna  | Employment | Self  |
| <i>Title:</i> Director of Immunology<br><i>Additional Information:</i> |            | <i>Position Description:</i> Research and Development |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization                                  |            |                              |
|--|------------|------------------------------|
| Entity   | Type       | Interest Held By             |
| Moderna  | Employment | Self                         |
| <i>Title:</i> Director<br><i>Additional Information:</i> |            | <i>Position Description:</i> |
| Moderna  | Stock      | Self                         |
| <i>Additional Information:</i>                           |            |                              |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-COV-2 Omicron Neutralization After mRNA-1273 Booster
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization   |            |                              |
|---|------------|------------------------------|
| Entity  | Type       | Interest Held By             |
| Moderna Therapeutics  | Employment | Self                         |
| <i>Title:</i> Sr. Manager - Clinical Biomarkers<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost,
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

# Bette Korber

Disclosure Purpose: 21-19912.R1

## Summary of Interests

### Company or Organization

| Entity   | Type             | Interest Held By  |
|--|------------------|---|
| <a href="#">National Institutes of Health</a>  | Grant / Contract | Self  |
| <i>Recipient Name:</i> Bette Korber<br><i>Grant / Contract Description:</i> NIH U19 AI142790<br><i>Additional Information:</i> |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

### Intellectual Property

| Type  | Is Licensed | Interest Held By   |
|---|-------------|--|
| <a href="#">Other Intellectual Property - Vaccine proposal for a second-generation SARS-Co ...</a>  | No          | Self   |
| <i>Description:</i> Vaccine proposal for a second-generation SARS-CoV-2 bivalent vaccine designed to improve cross-react<br><i>Licenses:</i>                                    |             | <i>Type:</i> To be filed : S133955 (DOE patent tracking number)<br><i>Additional Information:</i>              |
| <a href="#">Patent - Compositions and methods for treating coronaviru ...</a>   | No          | Self   |
| <i>Description:</i> Compositions and methods for treating coronavirus infection<br><i>Patent Status:</i> Provisional<br><i>Filing Jurisdiction:</i><br><i>Licenses:</i>         |             | <i>Patent Number:</i> 63/161318<br><i>Patent Holder:</i> Current Institution<br><i>Additional Information:</i> |
| <a href="#">Patent - Conserved region T cell vaccines for coronavirus ...</a>   | No          | Self   |
| <i>Description:</i> Conserved region T cell vaccines for coronavirus and methods of use<br><i>Patent Status:</i> Provisional<br><i>Filing Jurisdiction:</i><br><i>Licenses:</i> |             | <i>Patent Number:</i> 17/234590<br><i>Patent Holder:</i> Current Institution<br><i>Additional Information:</i> |

### Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost,
3. **Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19912.R1

## Summary of Interests

### Company or Organization

| Entity  | Type             | Interest Held By  |
|---|------------------|---|
| <a href="#">National Institutes of Health</a>   | Grant / Contract | Self  |
| <i>Recipient Name:</i> University of Maryland<br><i>Grant / Contract Description:</i> AI148689<br><i>Additional Information:</i> Research support |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Pfizer Inc.</a>   | Other            | Self  |
| <i>Category:</i> Other<br><i>Additional Information:</i> Receive salary support   |                  | <i>Description:</i> Clinical Investigator on COVID-19 trials.                   |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19912.R1

## Summary of Interests

### Company or Organization

| Entity  | Type             | Interest Held By  |
|---|------------------|---|
| <a href="#">Moderna</a>   | Grant / Contract | Self  |
| <i>Recipient Name:</i> David C. Montefiori<br><i>Grant / Contract Description:</i> Funding for neutralization assays on clinical samples from Moderna COVID-19 vaccine recipients |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research<br><i>Additional Information:</i> |
| <a href="#">National Institutes of Health</a>   | Grant / Contract | Self  |
| <i>Recipient Name:</i> David C. Montefiori<br><i>Grant / Contract Description:</i> NIH 75N93019C00050 Funding to support neutralization assays with SARS-CoV-2 variants           |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research<br><i>Additional Information:</i> |

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Rolando Pajon, PhD1, Nicole A. Doria-Rose, PhD2, Xiaoying Shen, PhD3, Stephen D Schmidt, BS2 Sijy O'Dell, MS2, Charlene McDanal, BS3, Wenhong Feng, MD3, Jin Tong, PhD3, Amanda Eaton, MBA3, Maha Maglinao, PhD1, Haili Tang, MS3, Kelly E. Manning, MS, MPH4, Venkata-Viswanadh Edara, PhD4, Lili Lai, MD4, Madison Ellis, BS4, Kathryn M Moore, PhD4, Katharine Floyd, MA4, Stephanie L. Foster, PhD4, Christine Posavad, PhD5, Robert L. Atmar, MD11, Kirsten E. Lyke, MD7, Tongqing Zhou, PhD2, Lingshu Wang, PhD2, Yi Zhang, BS2, Martin R Gaudinski, MD2, Walker P Black, BS2, Ingelise Gordon, RN2, Mercy Guech, PhD2, Julie E Ledgerwood, DO2, John N Misasi, MD2, Alicia Widge, MD2, Nancy Sullivan2, Paul C. Roberts, PhD8, John H Beigel, MD8, Bette Korber, PhD9, Lindsey R Baden, MD10, Hana El Sahly, MD11, Spyros Chalkias, MD1, Honghong Zhou, PhD1, Jing Feng, MS1, Bethany Girard, PhD1, Rituparna Das, MD1, Anne Aunins, PhD1, Darin K. Edwards, PhD1, Mehul S. Suthar, PhD4, John R. Mascola, MD2

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization  |            |                              |
|--|------------|------------------------------|
| Entity   | Type       | Interest Held By             |
| Moderna Inc.   | Employment | Self                         |
| <i>Title:</i> Director Clinical Biomarkers<br><i>Additional Information:</i> |            | <i>Position Description:</i> |
| Moderna Inc.   | Stock      | Self                         |
| <i>Additional Information:</i>   |            |                              |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boos
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization   |                  |   |
|---|------------------|---|
| Entity  | Type             | Interest Held By  |
| National Institutes of Health   | Grant / Contract | Self  |
| <i>Recipient Name:</i> Xiaoying Shen<br><i>Grant / Contract Description:</i> NIH 75N93019C00050<br><i>Additional Information:</i> Funding to support neutralization assays with SARS-CoV-2 variants |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization        |            |   |
|--------------------------------|------------|---|
| Entity                         | Type       | Interest Held By  |
| <a href="#">ModernaTX</a>      | Consultant | Self  |
| <i>Category:</i> Consultant    |            | <i>Description:</i> Consultation service to ModernaTX on the Epidemiology COVID-19 Variant Advisory Board |
| <i>Additional Information:</i> |            |   |
| <a href="#">Ocugen</a>         | Consultant | Self  |
| <i>Category:</i> Consultant    |            | <i>Description:</i> I serve in an advisory role for Ocugen  |
| <i>Additional Information:</i> |            |   |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- 1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
2. **What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization after mRNA-1273 Boost
3. **Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

| Company or Organization   |            |  |
|---|------------|--|
| Entity  | Type       | Interest Held By                           |
| Moderna   | Employment | Self                                       |
| <i>Title:</i> Sr. Director<br><i>Additional Information:</i>  |            | <i>Position Description:</i> Biostatistics |
| Moderna   | Stock      | Self                                       |
| <i>Additional Information:</i> As an employee of Moderna, i am also a stock holder of Moderna stock |            |  |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-19912.R1

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
SARS-CoV-2 Omicron Neutralization After mRNA-1273 Boost
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.